Humacyte's (HUMA) "Buy" Rating Reaffirmed at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Humacyte (NASDAQ:HUMA - Free Report) in a report published on Monday morning,Benzinga reports. D. Boral Capital currently has a $25.00 target price on the stock.

A number of other analysts have also weighed in on the company. Benchmark lowered their target price on Humacyte from $17.00 to $14.00 and set a "buy" rating for the company in a report on Wednesday, May 14th. Wall Street Zen raised Humacyte from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. Finally, HC Wainwright started coverage on Humacyte in a research report on Wednesday, May 14th. They set a "buy" rating and a $4.00 price objective on the stock. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, Humacyte has an average rating of "Moderate Buy" and an average price target of $11.71.

Humacyte Stock Down 5.1%

NASDAQ:HUMA traded down $0.13 during mid-day trading on Monday, reaching $2.41. The company's stock had a trading volume of 3,187,722 shares, compared to its average volume of 3,850,992. Humacyte has a 1 year low of $1.15 and a 1 year high of $9.79. The stock has a fifty day moving average of $1.86 and a 200-day moving average of $3.19. The firm has a market capitalization of $373.84 million, a PE ratio of -1.80 and a beta of 2.00.

Humacyte (NASDAQ:HUMA - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.09. The business had revenue of $0.52 million during the quarter, compared to analysts' expectations of $0.46 million. On average, analysts expect that Humacyte will post -1.27 earnings per share for the current year.

Insider Transactions at Humacyte

In related news, CFO Dale A. Sander purchased 20,000 shares of the business's stock in a transaction on Thursday, April 10th. The shares were acquired at an average price of $1.53 per share, for a total transaction of $30,600.00. Following the purchase, the chief financial officer now owns 40,600 shares of the company's stock, valued at $62,118. This trade represents a 97.09% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Kathleen Sebelius purchased 50,000 shares of the firm's stock in a transaction on Tuesday, April 8th. The stock was bought at an average cost of $1.32 per share, with a total value of $66,000.00. Following the acquisition, the director now owns 91,207 shares of the company's stock, valued at approximately $120,393.24. The trade was a 121.34% increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders have acquired 83,993 shares of company stock valued at $118,224. Corporate insiders own 5.10% of the company's stock.

Hedge Funds Weigh In On Humacyte

Several hedge funds have recently made changes to their positions in the company. Endowment Wealth Management Inc. lifted its position in Humacyte by 3.6% during the 4th quarter. Endowment Wealth Management Inc. now owns 104,108 shares of the company's stock worth $526,000 after acquiring an additional 3,590 shares during the period. Beacon Pointe Advisors LLC lifted its holdings in shares of Humacyte by 33.3% during the fourth quarter. Beacon Pointe Advisors LLC now owns 20,000 shares of the company's stock worth $101,000 after purchasing an additional 5,000 shares during the period. Rhumbline Advisers lifted its holdings in shares of Humacyte by 4.6% during the fourth quarter. Rhumbline Advisers now owns 114,455 shares of the company's stock worth $578,000 after purchasing an additional 5,005 shares during the period. Teacher Retirement System of Texas boosted its position in Humacyte by 25.3% in the fourth quarter. Teacher Retirement System of Texas now owns 26,200 shares of the company's stock valued at $132,000 after buying an additional 5,293 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its holdings in Humacyte by 20.7% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 33,870 shares of the company's stock worth $172,000 after buying an additional 5,801 shares during the period. 44.71% of the stock is owned by institutional investors and hedge funds.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.